

PROVINCIAL FUNDING SUMMARY

Crizotinib (Xalkori) for ROS1-positive advanced Non-Small Cell Lung Cancer (pCODR 10151)

pERC Recommendation: Recommends with conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: June 7, 2019

This information is current as of September 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Jul 1, 2020	Advanced non-small cell lung cancer <ul style="list-style-type: none"> Laboratory confirmed ROS1-positive tumour defined as either IHC 3+ or FISH positive □ First-line monotherapy ECOG 0-2 Asymptomatic/stable brain metastases (if applicable)
AB	Funded	Jul 30, 2020	Crizotinib single agent as first line treatment for patients with ROS1-positive non-small cell lung cancer (NSCLC). Treatment should continue until unacceptable toxicity or disease progression.
SK	Funded	Aug 1, 2020	<ul style="list-style-type: none"> First-line single agent treatment for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) Patients should have good performance status in the judgement of the physician; treatment may continue until unacceptable toxicity or disease progression
MB	Under provincial consideration		
ON	Under provincial consideration		
NS	Under provincial consideration		
NB	Funded	Jul 16, 2020	As monotherapy for the first-line treatment of patients with ROS1-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer. Renewal Criteria: Written confirmation that the patient is responding to treatment.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
			Clinical Note: Treatment should be discontinued upon clinically meaningful disease progression or unacceptable toxicity. Claim Notes: • Initial approval period: 1 year. • Renewal approval period: 1 year.
NL	Funded	May 1, 2020	For first-line treatment for patients with ROS1-positive non-small cell lung cancer (NSCLC) as monotherapy, with an ECOG performance status of 0-2. Renewal Criteria: Written confirmation that the patient has responded to treatment and there is no evidence of disease progression. Claim Notes: - Approval period: 6 months - Recommended Dose: 250mg twice daily
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.